These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Inflammatory bowel disease: an overview]. Herrlinger K Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117 [TBL] [Abstract][Full Text] [Related]
9. Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey. Lasch K; Liu S; Ursos L; Mody R; King-Concialdi K; DiBonaventura M; Leberman J; Dubinsky M Adv Ther; 2016 Oct; 33(10):1715-1727. PubMed ID: 27509887 [TBL] [Abstract][Full Text] [Related]
10. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Agrawal M; Colombel JF Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):421-436. PubMed ID: 31078245 [TBL] [Abstract][Full Text] [Related]
11. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Garg SK; Croft AM; Bager P Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009400. PubMed ID: 24442917 [TBL] [Abstract][Full Text] [Related]
12. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
13. Clinical and therapeutic characterisation of a multicentre cohort of patients with inflammatory bowel disease in Colombia. Parra-Izquierdo V; Flórez Sarmiento C; Frías-Ordoñez JS; Vargas M; Kock J; Lozano Escobar N; Márquez JR Gastroenterol Hepatol; 2023 Oct; 46(8):585-593. PubMed ID: 36464080 [TBL] [Abstract][Full Text] [Related]
14. [Current concepts about the treatment of inflammatory bowel disease, biological therapy]. Bosques-Padilla FJ; Galindo-Marines SL; Yamamoto-Farusho JK Rev Gastroenterol Mex; 2008; 73(4):217-30. PubMed ID: 19666271 [TBL] [Abstract][Full Text] [Related]
15. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118 [TBL] [Abstract][Full Text] [Related]
17. The state of the art in the management of inflammatory bowel disease. Hanauer SB; Present DH Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005 [TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
19. Classical and recent advances in the treatment of inflammatory bowel diseases. Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162 [TBL] [Abstract][Full Text] [Related]
20. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]